Evidence-Based Treatment for a Patient with Locally Advanced Non-Small Cell Lung Cancer_Chinese Journal of Evidence-Based Medicine

Authors：

ZHANG Jing , LEI Junrong , LUO Guoshi , LEI Huaiding ,  TU Mingli

Taihe Hospital Affiliated with the Yun yang Medical College, Hubei Shiyan 442000, China;

Corresponding author：

TU Mingli, Email: tumingli@tom.com

Keywords：

Cacinoma; Non-small cell lung; Advanced; Evidence-based treatment

DOI：

10.7507/1672-2531.20100230

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To make an individulized treatment plan for a patient with locally advanced non-small cell lung cancer (NSCLC).
Methods 　After clinical problems were put forward, evidence was collected from http://www. nccn.org. The Cochrane Library (Issue 4, 2008), Medline (PubMed 1990. 1-2008.11) and CHKD periodical database were searched.
Results 　A total of 21 RCTs, 5 systematic reviews and 13 CT phase Ⅲ trials were identified. A rational treatment plan was made upon a serious evaluation of the data. After nine monthes of follow-up, the plan was proved optimal.
Conclusion 　For locally advanced NSCLC patients, an individulized treatment plan made by evidence-based methods not only can inprove the treatment efficacy but also can lead both of doctors and patients to assume the indeterminateness of medicine.

Citation： ZHANG Jing,LEI Junrong,LUO Guoshi,LEI Huaiding,TU Mingli. Evidence-Based Treatment for a Patient with Locally Advanced Non-Small Cell Lung Cancer. Chinese Journal of Evidence-Based Medicine, 2010, 10(1): 94-96. doi: 10.7507/1672-2531.20100230 Copy

1.	Bonfill X, Serra C, Sacristán M, et al. Second-line chemotherapy for non-small cell lung cancer. Cochrane Database of Systematic Reviews 2001, Issue 4.
2.	Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmall- cell lung cancer: Results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 2005, 366(9496): 1527-1537.
3.	Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to Gefitinib therapy. Science, 2004, 304(5676): 1497-1500.
4.	Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to Gefitinib responsiveness in Taiwan. Clin Cancer Res, 2004, 10(24): 8195-8203.
5.	潘振奎, 张力, 张星, 等. 中国非小细胞肺癌患者表皮生长因子受体突变的研究. 癌症, 2005, 24(8): 919-923.
6.	管忠震, 张力, 李龙芸, 等. 吉非替尼治疗局部晚期或转移性非小细胞肺癌在中国的临床研究. 癌症, 2005, 24(8): 980-984.
7.	Cersosimo RJ. Gefitinib: A new antineoplastic for advanced nonsmall- cell lung cancer. Am J Health Syst Pharm, 2004, 61(9): 889-898.
8.	Kim ES, Hirsh V, Mok T, et al. Gefitinib versus Docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet, 2008, 372(9652): 1809-1818.
9.	Sackett DL, Straus SE, Richardson WS, et al. Evidence-based medicine: How to practice and teach EBM?.2nd ed. London: Churchill Livingstone, 2000: 1-240.

1. Bonfill X, Serra C, Sacristán M, et al. Second-line chemotherapy for non-small cell lung cancer. Cochrane Database of Systematic Reviews 2001, Issue 4.
2. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmall- cell lung cancer: Results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 2005, 366(9496): 1527-1537.
3. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to Gefitinib therapy. Science, 2004, 304(5676): 1497-1500.
4. Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to Gefitinib responsiveness in Taiwan. Clin Cancer Res, 2004, 10(24): 8195-8203.
5. 潘振奎, 张力, 张星, 等. 中国非小细胞肺癌患者表皮生长因子受体突变的研究. 癌症, 2005, 24(8): 919-923.
6. 管忠震, 张力, 李龙芸, 等. 吉非替尼治疗局部晚期或转移性非小细胞肺癌在中国的临床研究. 癌症, 2005, 24(8): 980-984.
7. Cersosimo RJ. Gefitinib: A new antineoplastic for advanced nonsmall- cell lung cancer. Am J Health Syst Pharm, 2004, 61(9): 889-898.
8. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus Docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet, 2008, 372(9652): 1809-1818.
9. Sackett DL, Straus SE, Richardson WS, et al. Evidence-based medicine: How to practice and teach EBM?.2nd ed. London: Churchill Livingstone, 2000: 1-240.

Chinese Journal of Evidence-Based Medicine

Evidence-Based Treatment for a Patient with Locally Advanced Non-Small Cell Lung Cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content